Novartis Secures FDA Priority Review For Brolucizumab Thanks To PRV
Novartis used a priority review voucher for brolucizumab, positioning the eye drug for a US launch in late 2019 if the FDA review goes smoothly.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.